Upregulation of Fas in epithelial ovarian cancer reverses the development of resistance to Cisplatin

19Citations
Citations of this article
28Readers
Mendeley users who have this article in their library.

Abstract

This study was to investigate the role of Fas in the development of Cisplatin-resistant ovarian cancer. On the cellular level, Fas expression was significantly reduced in Cisplatin resistant A2780 (A2780/CP) cells compared with A2780 cells. Fas silence with siRNA would promote tumor cell lines proliferation, facilitate tumor cell cycle transition of G1/S, prevent cell apoptosis, and promote cell migration. Expression of drug resistance gene was negatively correlated to Fas. In nude mice metastasis model of human ovarian carcinoma by subcutaneous transplantation, after Ad-Fas injected intratumorly, we found that upregulation of Fas could inhibit transplantation tumor tissue growth and reduce the expression of drug resistance gene. Our results indicated that upregulation of Fas in epithelial ovarian cancer reversed the development of resistance to Cisplatin. In conclusion, our findings suggested that Fas might act as a promising therapeutic target for improvement of the sensibility to Cisplatin in ovarian cancer.

Cite

CITATION STYLE

APA

Yang, F., Long, W., Xuechuan, H., Xueqin, L., Hongyun, M., & Yonghui, D. (2015). Upregulation of Fas in epithelial ovarian cancer reverses the development of resistance to Cisplatin. BMB Reports, 48(1), 30–35. https://doi.org/10.5483/BMBRep.2015.48.1.042

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free